Safety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children
Condition: Pediatric Growth Hormone Deficiency Interventions: Drug: MOD-4023; Drug: Somatropin Sponsor: Opko Biologics Not yet recruiting - verified October 2016
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials